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Tumor progressionMicroRNAs (miRNA) have played an important role in carcinogenesis. In this study, Agilent miRNA
microarray was used to identify differentially expressed miRNAs in esophageal squamous cell carci-
noma (ESCC) tissues and miR-195 was downregulated in ESCC compared with normal esophageal
tissues. Moreover, Cdc42 was conﬁrmed as target gene of miR-195. Ectopic expression of miR-195
in ESCC cells signiﬁcantly downregulated Cdc42 by directly binding its 30 untranslated regions,
and induced G1 cell cycle arrest, leading to a signiﬁcant decrease in cell growth, migration, and inva-
sion in vitro. Therefore, our ﬁndings demonstrated that miR-195 may act as a tumor suppressor in
ESCC by targeting Cdc42.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Esophageal cancer is the sixth leading cause of cancer-related
deaths and the eighth most common cancer in the world [1]. His-
tologically, esophageal cancer can be divided into two main sub-
types, i.e., esophageal squamous cell carcinoma (ESCC) and
esophageal adenocarcinoma (EAC). The incidence of ESCC is higher
in East Asia, especially in China, while EAC incidence is higher in
Western countries such as the USA [2]. These two types of esoph-
ageal cancer have relatively different etiologic characteristics and
risk factors, but both are frequently diagnosed at the advanced
stages of disease, which make cure extremely difﬁcult. Thus, their
overall 5-year survival rate is still less than 10–15% [3]. Therefore,
it is urgent to discover molecular biomarkers for early tumor
detection and novel therapeutic strategies.
To this end, our research has been focused on microRNAs
(miRNA), which are a class of small, highly-conserved, single-
stranded, non-coding RNAs with approximately 17–25 nucleotides.
Functionally, they can target the 30-untranslated region (UTR) of
their target messenger RNAs to regulate their expression through
direct mRNA degradation or they can block translation [4]. Thus,miRNAs participate in different biological and pathologic processes
in the human body and play important regulatory roles in cell dif-
ferentiation, proliferation, apoptosis, and metabolism [5]. Recent
studies showed that aberrant expression of miRNAs can function
as tumor suppressors or oncogenes [6–9] and many miRNAs have
also been reported in the development and progression of ESCC
[10,11]. For example, miR-375 was reported to be down-regulated
in ESCC tissues and cell lines and can inhibit tumor growth and
metastasis by repressing IGF1R expression [12]. miR-25 and miR-
223 were up-regulated in ESCC tissue [13,14].
In this study, we ﬁrst used Agilent microarrays to identify differ-
entially expressed miRNAs in ESCC tissues vs. the paired adjacent
normal tissues. The detailed date on these three samples used for
microarray analysis was showed in Table 1. We then chose one of
these differentially expressed miRNAs, miR-195 for further study
in ESCC tissues and cells as miR-195 has been shown to be up-reg-
ulated in breast cancer but down-regulated in colorectal cancer and
squamous cell carcinoma of the tongue [15–17]. Bioinformatic
studies have shown that miR-195 may target Cdc42, a member of
Rho GTPase family, which has functions in cell polarity, prolifera-
tion, migration, and gene transcription [18]. Cdc42was also up-reg-
ulated in many human cancers, including head and neck cancer
[19], colorectal cancer [20], and ESCC [21]. Thus, we investigated
the effects of miR-195 expression in the regulation of cell viability,
colony formation, and gene expression in ESCC cells.
Table 1
Clinicopathological features of 3 ESCC patients for subjection of Agilent microarray
analysis.
Sample Age,
years
Sex Clinical
stage
Distant
metastasis
Tumor size
(cm)
1 55 Male I—II M0 4*3*1.5
2 59 Male II—III M0 4*2*1
3 71 Female II—III M0 3.5*2*1.5
Fig. 1. Differentially expressed miRNAs in esophageal squamous cell carcinoma as
detected by microarray anlaysis. Three pairs of esophageal carcinoma and normal
tissues were analyzed by Agilent microarrays. For each miRNA, yellow represents
higher expression and blue represents lower expression than the average expres-
sion. T1, tumour1; N1, normal1; T2, tumour2; N2, normal2; T3, tumour3; N3,
normal3.
Table 2
Differential expression of miRNAs in ESCC vs. normal tissues.
Up-regulation Fold change Down-regulation Fold change
Hsa-miR-424 6.75 Hsa-miR-195 2.63
Hsa-miR-223 6.30 Hsa-miR-133b 17.95
Hsa-miR-21 3.93 Hsa-miR-99a 4.01
Hsa-miR-19a 2.79 Hsa-miR-29c 2.12
Hsa-miR-185 2.35 Hsa-miR-145 10.72
Hsa-miR-4306 2.31 Has-miR-100 2.84
Hsa-miR-20b 2.27 Hsa-miR-1 9.54
Hsa-miR-3651 2.21 Hsa-miR-143 6.88
Hsa-miR-106b 2.18
Hsa-miR-429 2.01
Fig. 2. Taqman real-time PCR detection of miR-195 expression in ESCC, dysplasia,
and normal tissues. (A) Loss of miR-195 expression in ESCC vs. normal tissues. N,
normal; T, tumor. (B) miR-195 was not signiﬁcantly down-regulated in dysplastic
vs. normal tissues. N, normal; D, dysplasia. U6 mRNA served as an internal control.
⁄P < 0.05.
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2.1. Tissue samples
Surgically removed human ESCC and matched normal esopha-
geal tissues (5 cm away from tumor) were collected and ninepaired esophageal dysplasia tissues and adjacent normal tissues
were obtained from patients who underwent endoscopic surgery
from Jiangsu Province Hospital (Jiangsu, China). All patients had
not received any treatment before surgery. All tissues were
snap-frozen in liquid nitrogen immediately and then stored at
80 C until use. The study was approved by the committees for
ethical review of research of the First Afﬁliated Hospital of Nanjing
M.-g. Fu et al. / FEBS Letters 587 (2013) 3471–3479 3473Medical University. A written informed consent form was signed
by each participant.
2.2. Cell lines and culture
Human ESCC cell lines TE13 and Eca109 were obtained from the
Shanghai Institute of Biochemistry and Cell Biology (Shanghai, Chi-
na). TE13 cells were cultured in Dulbecco’s modiﬁed Eagle’s med-
ium (DMEM) supplemented with 10% fetal bovine serum (FBS),
100 U/ml penicillin and 100 lg/ml streptomycin. Eca109 cells were
cultured in Rosewell Park Memorial Institute (RPMI)-1640 medium
with 10% FBS, 100 U/ml penicillin and 100 lg/ml streptomycin
(Gibco, Gaithersburg, MD, USA) in a humidiﬁed 5.0% CO2 atmo-
sphere at 37 C.
2.3. miRNA microarray analysis
To proﬁle differentially expressed miRNA in ESCC vs. normal
tissues, we performed miRNA microarray analysis. In brief, total
cellular RNA was ﬁrst isolated from three pairs of ESCC tumor
and corresponding distant non-cancerous tissues using an mir-
Vana™ miRNA isolation kit (Applied Biosystem, Austin, TX, USA)
and then reverse transcribed into cDNA probes using a miRNA
complete labeling and Hyb kit (Agilent, Technologies, Inc., Santa
Clara, CA, USA). After that, the labeled probes were hybridized
onto three miRNA microarray (Agilent) according to the manufac-
turer’s instructions. The arrays were scanned and the data were
extracted and analyzed using Agilent Feature Extraction (v10.7)
software and the Agilent GeneSpring software for data were
normalized.
2.4. RNA isolation and qRT-PCR
Total RNA was isolated from tissue specimens and cell lines by
using the Trizol reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions and 10 ng of RNA samples were
reverse transcribed into cDNA using a TaqMan MicroRNA reverse
transcription kit. Real-time PCR was performed using standard
TaqMan PCR reagents and TaqMan MicroRNA assays for hsa-miR-
195 and U6 (Applied Biosystems). The U6 mRNA was used as an
internal control for miR-195. Furthermore, RNA samples from ESCC
cells were also reverse transcribed into cDNA by using a Reverse
Transcriptase kit (TaKaRa, Dalian, China) for qRT-PCR detection ofFig. 3. Bioinformatic analysis of miR-195 targeting gene. 30UTR of cdc42 mRNA
contains a putative miR-195 target site. (A) Bioinformatics tools predicted that the
binding region of miR-195 is localized at 23–29 nt of 30UTR of Cdc42 mRNA. (B)
Sequence analysis indicated that miR-195 target sequence at 23–29 nt of cdc42
30UTR is highly conserved across different species.
Fig. 4. miR-195 regulation of Cdc42 expression by targeting its 30UTR in ESCC cell
lines. (A) Luciferase assay. The interaction of miR-195 with Cdc42 was conﬁrmed by
Luciferase assay in Eca109 cells. (B) Western blot. Expression of miR-195 or Cdc42
siRNA could inhibit expression of Cdc42 protein in Eca109 and TE13 cells. ⁄P < 0.05.
(C) Real-time PCR. Cdc42 mRNA was not regulated by miR-195 in Eca109 and TE13
cells.
Fig. 5. Effect of miR-195 mimics and inhibitor transfection on modulation of miR-
195 expression in Eca109 and TE13 cell lines. ⁄⁄P < 0.01.
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Premix Ex Taq kit (Applied Biosystems). The Cdc42 primers were
50-CCATCGGAATATGTACCGACTG-30 and 50-CTCAGCGGTCGTAATCT
GTCA-30 and GAPDH primers were 50-CGGAGTCAACGGATTTGGTCG
TAT-30 and 50-AGCCTTCTCCATG GTGGTGAAGAC-30. Each sample
was run in triplicate. Expression levels of miRNA, mature mRNAs,
or Cdc42 were calculated using the comparative CT method
(2DDCT).
2.5. Transient gene transfection into ESCC cell lines
hsa-miR-195 mimic (50-UAGCAGCACAGAAAUAUUGGC-30 and
50-CAAUAUUUCUGUGCUGCUAUU-30) and negative control oligo-
nucleotides (50-UCCUCCGAACGUGUCACGUTT-30 and 50-ACGUGA
CACGUUCGGAGAATT-30), miR-195 inhibitor (50-GCCAAUAUUUCU-
GUGCUGCUA-30), NC for miRNA-195 inhibitor (50-CAAUAUUUCU-
GUGCUGCUAUU-30) and small interfering Cdc42 (si-Cdc42, 50-
CCUCUACUAUUGAGAAACUdTdT-30 and 30-dTdTGGAGAUGAUAAC
UCUUUGA-50) were purchased from Genepharma (Shanghai,
China). ESCC cells were seeded and grown overnight and the nextFig. 6. Effect of miR-195 expression or Cdc42 knockdown on regulation of ESCC cell via
transfected with miR-195 mimic,Cdc42 siRNA, and miR-195 inhibitor grown for up to 4day, these RNA oligonucleotides were transiently transfected into
cells using Lipofectamine 2000 (Invitrogen) according to the man-
ufacturer’s protocol. 48 h later, the cells were subjected to different
experiments, as below.
2.6. Cell viability assay
TE13 and Eca109 cells transfected with or without transfection
of aforementioned RNA oligonucleotides for 24 h, were seeded in
96-well plates (3000 cells/well) and cultured for up to 96 h. At
the end of each experiment, reagents from the Cell Counting Kit-
8 (CCK-8, Beyotime, Beijing, China) were added to each well, and
the optical density (OD) was measured. The experiment was per-
formed in 6 replicates and repeated once.
2.7. Colony formation assay
ESCC cells transfected with RNA oligonucleotides for 48 h and
control ESCC cells were seeded into 6-well plates (300 cells/well)
and cultured at 37 C for two weeks. At the end of the incubationbility and clonogenicity. (A) Cell viability CCK-8 assay. Eca109 and TE13 cells were
days and then subjected to CCK-8 assay. (B) Colony formation assay. ⁄P < 0.05.
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ine (PBS) and ﬁxed with methanol for 15 min before staining with
0.4% crystal violet at room temperature for 30 min. Plates were
then washed with PBS and left to dry. The cell colonies with
50 cells or more were counted. Each assay was performed in
triplicate.
2.8. Tumor cell migration and invasion assay
Tumor cell migration was assayed by using 24-well Transwell
plates with 8 mm pore size (Millipore, Bedford, MA, USA).
Brieﬂy, cells after 48 h transfection were seeded into the top
chambers with 0.2 ml culture medium containing 1  105 cells
with 1% FBS, while 0.6 ml of 20% FBS-containing medium was
added to the bottom chambers. After 48 h incubation at 37 C,
cells that migrated onto the lower surface of the membrane
were ﬁxed with 95% ethanol for 15 min, stained with 0.4% crys-
tal violet at room temperature for 30 min, and then counted in
at least ﬁve random microscopic ﬁelds (100). For the tumor
cell invasion assay, the membranes were coated with Matrigel,
and all other procedures were performed similarly as for the
migration assay.Fig. 7. Regulation of cell cycle distribution by miR-195 expression. Eca109 (A) and TE13
subjected to ﬂow cytometric analysis of cell cycle distribution. The results showed that2.9. Flow cytometry
To analyze cell cycle distribution, we performed ﬂow cytome-
try. In brief, the cells were transfected with the above named
RNA oligonucleotides for 48 h and then harvested via trypsiniza-
tion and washed with PBS twice, before ﬁxing in 70% ethanol over-
night at 4 C. The samples were then stained with propidium
iodide (PI)/RNase and analyzed using ﬂuorescence activated cell
sorter (FACS, BD Biosciences, Mountain View, CA, USA) scan. The
percentage of cells in G1/S/G2/M-phase was used to calculate the
proliferative index.
2.10. Luciferase assay
To assay miR-195 binding to the Cdc42 30-UTR region, we per-
formed a luciferase assay. Speciﬁcally, we synthesized a fragment
of the Cdc42 30-UTR that contained the putative miR-195 binding
sites and cloned downstream into the luciferase gene in the pGL3
luciferase vector (Invitrogen). For reporter assays, Eca109 cells
were co-transfected with pGL3-30-UTR-wt and miR-195 mimics
or negative control oligonucleotides (NC) for 48 h. Fireﬂy and
Renilla luciferase activities were measured by Dual Luciferase(B) cells were transfected with miR-195 mimic or Cdc42 siRNA for 48 h and then
miR-195 or Si-Cdc42 could induce cell cycle G1 arrest. ⁄P < 0.05.
Fig. 8. Inhibition of tumor cell migration and invasion by miR-195 expression or
Cdc42 knockdown in ESCC cells. miR-195 mimic or Cdc42 knockdown inhibited
Eca109 cell migration (A) and invasion (B), whereas anti-miR-195 promoted Eca109
cell migration (C) and invasion (D). ⁄P < 0.05.
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turer’s instructions. The data were normalized against the activity
of the Renilla luciferase gene. Three independent experiments
were performed in triplicate.
2.11. Protein extraction and Western blot
Total cell lysates were prepared by using a RIPA buffer (50 mM
Tris–HCl pH 7.4, 10 mM NaCl, 1% NP-40, 0.5% sodium deoxycho-
late, and 0.1% SDS). Protein concentration was measured by the
BCA method (Beyotime). Equal amounts of protein extracts were
separated by 10% SDS–polyacrylamide gels and transferred onto
PVDF membranes (Millipore). The membranes were then blocked
with 5% non-fat milk powder at room temperature for 1 h and
incubated with a primary antibody against Cdc42 or GAPDH (Cell
Signaling Technology, Inc., Danvers, MA) at 4 C overnight and fur-
ther incubated with a horseradish peroxidase-conjugated second-
ary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for
1 h at room temperature. Alpha Innotech (San Leandro, CA) imag-
ing software was used to quantify Western blot data.
2.12. Statistical analysis
The data were summarized as mean ± S.D. and analyzed by
using Student’s t test and Chi-square test using SPSS 16.0 software
(SPSS, Chicago, IL). A P value less than 0.05 was considered to be
statistically signiﬁcant.
3. Results
3.1. miRNA expression proﬁling in human ESCC vs. normal tissues
In this study,we performedmiRNAmicroarray analysis to proﬁle
differentially expressed miRNAs in ESCC vs. normal tissues. We de-
tected expression of 1347 miRNAs in three pairs of ESCC vs. normal
tissues. Taking a twofold difference as the cut-off point, we identi-
ﬁed 10 up-regulated and 8 down-regulated miRNAs in these three
pairs of ESCC vs. corresponding non-tumor tissues (Fig 1 and Ta-
ble 2). Among these 18 differentially expressedmiRNAs, manymiR-
NAs had been shown in other studies to be differentially expressed
in ESCC; for example, miR-223 was able to regulate migration and
invasion by targeting Artemin in esophageal carcinoma cells [22]
and miR-145 acts a tumor-suppressor miRNA in ESCC by target
FSCN1 [23]. Thus, we chose miR-195 for further study in ESCC.
3.2. Downregulation of miR-195 in ESCC tissues
Our study objective is to understand the molecular mechanisms
responsible for ESCC progression; thus, we performed a bioinfor-
matic search of TargetScan, miRDB, Miranda, and PicTar databases
and found that miR-195 may target Cdc42, which controls diverse
cellular functions including cell morphology, migration, endocyto-
sis and cell cycle progression [24]. Thus, we further focused on
miR-195 by detecting its expression in 18 pairs of ESCC tissues
and 9 pairs of esophageal dysplasia tissues using Taqman Real-
time PCR. We found that miR-195 expression was reduced in ESCC
tissues (Fig. 2A, P < 0.05) but no statistically signiﬁcant changes in
dysplasia tissues were found compared to their corresponding nor-
mal tissues (Fig. 2B).
3.3. Expression of miR-195 inhibited Cdc42 expression in ESCC cell
lines
Bioinformatic analysis of TargetScan, miRDB, Miranda, and Pic-
Tar databases showed that the miR-195 binding region was locatedat the 23–29 nt region of 30UTR of Cdc42 gene and that the target
sequences were highly conserved among different species (Fig. 3).
To validate this, we performed a luciferase reporter assay and
found that miR-195 transfection signiﬁcantly decreased luciferase
activities compared to the control oligonucleotide and pGL3-
Cdc42-wt group. Fig. 4A (P < 0.05) suggested that Cdc42 is a target
gene of miR-195. Moreover, we performed real-time PCR and wes-
tern blot analysis of Cdc42 mRNA and protein levels respectively,
in ESCC cells transfected with miR-195 mimic. Our data showed
that Cdc42 protein levels were signiﬁcantly reduced in miR-195-
transfected tumor cells compared to the controls (Fig. 4B,
P < 0.05). However, miR-195 did not modulate levels of Cdc42
mRNA miR-195-transfected cells compared to the controls
(Fig. 4C), indicating that this regulation is post-transcriptional.
3.4. Expression of miR-195 changed in ESCC cell phenotypes in vitro
As shown in Fig. 5, after transfected with miR-195 mimics and
inhibitor, level of miR-195 expression in Eca109 and TE13 cells was
up or downregulated compared to the control miRNAs.
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of tumor cell growth and found that overexpression of miR-195 or
knockdown of Cdc42 expression slightly reduced viability of
Eca109 and TE13 cells, whereas anti-miR-195 induced tumor cell
viability (Fig. 5A). Moreover, the colony formation assay showed
that miR-195mimic or knockdown of Cdc42 expression suppressed
colony forming efﬁciency of tumor cells, whereas anti-miR-195 in-
creased colony forming efﬁciency of Eca109 cells (Fig. 6B).
In addition, the ﬂow cytometry assay showed that tumor cells
transfected with miR-195 mimics or Si-Cdc42 were arrested in
the G1 phase of the cell cycle and that the S and G2/M phases
were also signiﬁcantly reduced compared to control cells
(Fig. 7A and B).Fig. 9. Regulation of gene expression by ectopic expression of miR-195 or Cdc42 knockd
for 72 h and then subjected to Western blot analysis of gene expression. The quantitativ3.5. Expression of miR-195 inhibited tumor cell migration and invasion
As displayed in Fig. 8, our data showed that tumor cell migra-
tion and invasion ability was signiﬁcantly reduced in cells transfec-
ted with miR-195 mimics or Si-Cdc42 compared to the controls
(P < 0.05). In contrast, tumor cell migration and invasion ability
was increased in cells transfected with anti-miR-195 oligonucleo-
tides (P < 0.05).
3.6. Expression of miR-195 suppressed Cdc42/ERK/Cyclin D1 signaling
To further investigate the underlying molecular events respon-
sible for miR-195 actions, we analyzed the downstream signals ofown. Eca109 and TE13 cells were transfected with miR-195b mimic or Cdc42 siRNA
e data are shown in the graphs. ⁄P < 0.05.
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phosphorylation ERK1/2, and cyclin D1]. As shown in Fig. 9,
phosphorylation levels of EKR1/2 and expression of cyclin D1 were
decreased signiﬁcantly in cells transfected with miR-195
mimics or Si-Cdc42, compared to cells transfected with control
oligonucleotides.4. Discussion
Recent studies have discovered many dysregulated miRNAs in
human cancers, which play an important role in cancer develop-
ment and progression [25,26]. Thus, in this study, we proﬁled
differentially expressed miRNAs in three pairs of ESCC vs. distant
non-tumor tissues. We found a large number of miRNA expressed
in esophageal tissues and identiﬁed 18 differentially expressed
miRNAs in ESCC tissues. miR-195 has been considered as a tumor
suppressor in adrenocortical cancer and hepatocellular cancer
[27,28]. Thus, we chose miR-195 for further study and found that
expression of miR-195 was down-regulated in ESCC and that
expression of miR-195 inhibited tumor cell viability, migration,
invasion, and colony formation in vitro. At the molecular level,
miR-195 suppressed expression of Cdc42 protein, ERK1/2 phos-
phorylation and cyclin D1 expression. Our data indicate that
altered expression of miRNAs could promote ESCC development
and that lost miR-195 expression may contribute to ESCC
progression.
To date, there are a number of published studies on miRNAs in
esophageal cancer [29–31]. For example, Guo et al. [29] analyzed
miRNA expression proﬁle in 31 ESCC and adjacent normal tissue
samples using miRNA microarrays. They found that the expression
levels of somemiRNAswere different between ESCC and normal tis-
sues, and miR-103/107 expression was associated with poor sur-
vival [29]. Hu et al. [31] showed that all 10 analyzed miRNAs were
altered in esophageal cancer tissues. Multivariate analysis showed
an association between overall or disease-free survival of ESCC
patients and miR-9, miR-16-2, miR-20, and miR-200a expression
[31]. Another study showed that increased miR-21 expression in
non-cancerous tissues of SCC patients was associated with worse
prognosis of the patients [32]. However, the data from our current
study did not show any overlap of these differentially expressed
miRNAs with previous studies. The reason is not clear, but it may
be because of different study population, technique used, and RNA
sample preparation (for example, different levels of tumor and nor-
mal tissue mixture could affect the levels of miRNA expression).
Our current data showed downregulation of miR-195 expres-
sion in ESCC and in some esophageal dysplasia tissues compared
to the matched distant normal tissues. However, the cause and
mechanism responsible for down-regulation of miR-195 in ESCC
remains unknown. Notably, miR-195 is a highly conserved miRNA
cluster localized at chromosome 17P13.1 [33], which is a fre-
quently deleted region in human cancers. In another aspect, Li
et al. [34] showed that DNA methylation was responsible for
miR-195 down-regulation in breast cancer. Thus, future studies
will investigate the cause of lost miR-195 in ESCC.
Furthermore, our study showed that expression miR-195 re-
duced tumor cell viability, migration, invasion, and colony forma-
tion in vitro. At the molecular level, miR-195 suppressed
expression of Cdc42 protein, ERK1/2 phosphorylation and cyclin
D1 expression. Indeed, a previous study showed that Cdc42 was
up-regulated in ESCC tissues and associated with lymph node
metastasis [21]. Cdc42 functions by regulating cell motility, prolif-
eration, and migration [24] by modulation of the PAK1, ERK1/2,
JNK, and p53 gene pathways. Activation of Cdc42 can weaken
c-Cbl-mediated EGFR degradation, promote EGFR hyperactivity,
and induce proteasome degradation of p21CIP1, leading to anincrease in cell proliferation and migration [35,36]. In addition,
dominant-negative mutants of Cdc42 were able to control three
major components of cellular signal transduction, namely, p53,
Akt, and ERK1/2 signal cascades. In turn, this led to restraint of
anchorage-independent growth and induced cell apoptosis [37].
In our study, we found that miR-195 was able to bind to the 30
UTR of Cdc42 mRNA and suppressed expression of Cdc42 protein.
In conclusion, our study further showed that expression of miR-
195 or knockdown of Cdc42 expression inhibited ERK1/2 phos-
phorylation and cyclinD1 expression in ESCC cells. Indeed, through
binding to and activation of cyclin-dependent kinase 4 (cdk4)/
cdk6, cyclinD1 can promote cell cycle progression [38]. Cyclin D1
is one of the D-type cyclins, reaches maximum activity in G1 per-
iod, and promotes cell cycle transition from G1 to S phase [39].
Welsh [40] found that Cdc42 contributed to promotion of cell cycle
transition from G1 to S phase. Furthermore, we also found that
miR-195 suppressed ESCC cell migration and invasion but we did
not pursue the underlying signal transduction pathways. Thus, fur-
ther investigation is needed to identify them.
In summary, our current study demonstrated that lost miR-195
expression contributed to ESCC progression through cell cycle ar-
rest and inhibition of Cdc42 expression, which may be further eval-
uated as a novel target for ESCC therapy.
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